Study details
Enrolling now
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
University of Miami
NCT IDNCT05607719ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 3 years
Ages
40–80
Locations
1 site in FL
About this study
Researchers are testing whether adding a short course of inhaled corticosteroids to your usual treatment for COPD improves how well your blood vessels respond to medication. The trial will last 1084 days and involve approximately 30 adults with stable COPD who are not currently taking an ICS.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Bevespi
- 2.Take Bretzri
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Percent change in FEV1
Body systems
Respiratory